Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

Novartis AG (NYSE:NVS) is one of the best cheap stocks to buy for beginners. Novartis AG (NYSE:NVS) announced on June 3 new Cosentyx® data in polymyalgia rheumatica showing a statistically significant ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novartis (SWX:NOVN) reported that its drug Cosentyx achieved significant Phase III results ...

Celltrion has launched its push into the North American market with a biosimilar candidate targeting one of the world's ...

Approval was supported by adult HS and psoriasis clinical trials, pharmacokinetic modeling, and data from established pediatric indications. The Food and Drug Administration (FDA) has approved ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated ...

Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥502, with limited options available Basel, October 22, 2025 - Novartis today ...